FGFR

Fibroblast growth factor receptor

FGFR

Related Products

FGFR (Fibroblast growth factor receptors) are the receptors that bind to members of the fibroblast growth factor family of proteins. Some of these receptors are involved in pathological conditions. A point mutation in FGFR3 can lead to achondroplasia. Five distinct membrane FGFR have been identified in vertebrates and all of them belong to the tyrosine kinase superfamily (FGFR1, FGFR2, FGFR3, FGFR4, FGFR6). The fibroblast growth factor family constitutes one of the most important groups of paracrine factors that act during development. They are responsible for determining certain cells to become mesoderm, for the production of blood vessels, for limb outgrowth, and for the growth and differentiation of numerous cell types.

FGFR Related Products (331)
Recombinant Proteins (68)
Antibodies (11)

By Effects:	Inhibitors (283) Agonists (3) Degraders (6) Activators (2) Modulators (3)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-143272

FGFR1 inhibitor-6	Inhibitor
FGFR1 inhibitor-6 is a potent FGFR1 inhibitor with an IC₅₀ value of 16.31 nM. FGFR1 inhibitor-6 shows cytotoxic activities. FGFR1 inhibitor-6 induces apoptosis and cell cycle arrest at pre-G1 and G2/M phase.

HY-172922

FGFR-IN-19	Inhibitor
Arg-IN-1 is a selective Arginine (Arg)-targeting covalent inhibitor with IC₅₀s of 9.7 nM and 30.4 nM for FGFR2 and FGFR3,respectively. Arg-IN-1 has the potential to avoid FGFR1/4-targeted toxicity as well as conquer acquired on-target resistance, potential for FGFR-targeting cancer therapy.

HY-P11162

FGF7p	Activator
FGF7p is a small molecule peptide and a potential bladder protector. FGF7p can activate downstream signaling pathways of FGFR2 in the urinary tract epithelium (pFRS2α, pAKT and pERK). FGF7p alleviates cyclophosphamide induced apoptosis and tissue damage in urinary tract epithelial cells by activating AKT and its downstream anti apoptotic targets (pBAD, pS6/mTORC1). FGF7p has the advantages of low cost, good stability, and high purity. FGF7p is commonly used in the study of inflammatory conditions.

HY-P5903

FGF acidic I (102-111) (bovine brain)
FGF acidic I (102-111) (bovine brain) (aFGF (102-111)) is the 102-111 fragment of acidic FGF that can be used as a potential neurotrophic agent.

HY-16135A

CEP-11981 tosylate	Inhibitor
CEP-11981 (tosylate) (ESK981 (tosylate), BOL 303213X (tosylate)) is an orally active tyrosine kinase inhibitor (TKI), which can target TIE2, VEGFR1-3 and FGFR1, and has potential anti-tumor and anti-angiogenic effects.

HY-E70820

FGFR2 L617V Recombinant Human Active Protein Kinase
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 L617V is a mutant of FGFR3. FGFR2 L617V Recombinant Human Active Protein Kinase is a recombinant FGFR2 L617V protein that can be used to study FGFR2 L617V-related functions.

HY-170934

BW710	Inhibitor
BW710 is an orally active fibroblast growth factor receptor 2 (FGFR2) inhibitor. BW710 inhibits the proliferation of BaF3-FGFR2 cells with an IC₅₀ of 2.8 nM. BW710 abolishes FGFR2 enzymatic activity and is selective against other 75 tyrosine kinases including FGFR1, FGFR3, and FGFR4 at 1 μM. BW710 suppresses the FGFR2 signaling and selectively inhibits FGFR2-driven cancer cell proliferation. BW710 displays reasonable pharmacokinetic properties with an oral bioavailability of 29 % in mice.

HY-P3695A

VSPPLTLGQLLS TFA	Inhibitor
VSPPLTLGQLLS TFA is a small peptide FGFR3 inhibitor, peptide P3, inhibits FGFR3 phosphorylation. VSPPLTLGQLLS TFA inhibits 9-cisRA-induced tracheal lymphangiogenesis and blocks lymphatic endothelial cell (LEC) proliferation, migration, and tubule formation.

HY-172923

FGFR-IN-20	Inhibitor
Glu-IN-1 (compound AF1) is a covalent and selective FGFR2 inhibitor with an IC₅₀ of 1.6 μM. Glu-IN-1 covalently modifies Glu489 in FGFR2.

HY-168286

FGFR-IN-16	Inhibitor
FGFR-IN-16 (compound 7N) is a potent inhibitor of FGFR1, FGFR2, and FGFR4, with the IC₅₀s of 8 nM, 4 nM and 3.8 nM, respectively. FGFR-IN-16 plays an important role in cancer research^1].

HY-145836

FGFR4-IN-8	Inhibitor
FGFR4-IN-8 (Compound 7v) is an ATP-competitive, highly selective covalent inhibitor of wild-type and gatekeeper mutant FGFR4. FGFR4-IN-8 exhibits excellent potency against FGFR4, FGFR4^V550L, FGFR4^V550M and FGFR4^C552S with IC₅₀s of 0.5, 0.25, 1.6, 931 nM, respectively. FGFR4-IN-8 exhibits potent antiproliferative activity against Hep3B hepatocellular carcinoma cells with the IC₅₀ value of 29 nM. FGFR4-IN-8 demonstrates modest in vivo antitumor efficacy in nude mice bearing the Huh-7 xenograft model.

HY-162626

FGFR2 degrader 1	Degrader
FGFR2 degrader 1 (compound 28E) is a selectively PROTACS degrader of FGFR2, with the DC₅₀ of 0.645 nM. FGFR2 plays an important role in cancer research (Pink: ligand of target protein; (HY-13304) black: linker; blue: ligand of E3 ligase).

HY-E70718

FGFR3 G697C Recombinant Human Active Protein Kinase
FGFR3 activating mutations are drivers of malignancy in several human tissues, including bladder, lung, cervix, and blood. FGFR3 G697C is a mutant of FGFR3 that may be present in oral squamous cell carcinoma. FGFR3 G697C increases FGFR3 auto-phosphorylation. FGFR3 G697C Recombinant Human Active Protein Kinase is a recombinant FGFR3 G697C protein that can be used to study FGFR3 G697C-related functions.

HY-E70821

FGFR2 M537I Recombinant Human Active Protein Kinase
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 M537I is a mutant of FGFR3. FGFR2 M537I Recombinant Human Active Protein Kinase is a recombinant FGFR2 M537I protein that can be used to study FGFR2 M537I-related functions.

HY-P991106

IMC-D11	Inhibitor
IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonal antibody against FGFR3. IMC-D11 can be used for the antibody part of LY3076226. IMC-D11 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-174974

ISM7594	Inhibitor
ISM7594 is an orally active FGFR2/3 inhibitor. ISM7594 shows broad-spectrum antiproliferative potency in FGFR2- or FGFR3-altered cancer cell panels, including FGFR2/3 amplification, fusion, and mutation (BaF3-TEL-FGFR2-V564F (IC₅₀ = 0.067 nM), BaF3-TEL-FGFR2-V564I (IC₅₀ = 2 nM)) types. ISM7594 inhibits tumor growth in a dose-dependent manner. ISM7594 can be used for the study of advanced solid tumors with FGFR2/3 aberrations.

HY-149512

FGFR1/VEGFR2-IN-1	Inhibitor
FGFR1/VEGFR2-IN-1 (compound 2b) is an FGFR1/VEGFR2 inhibitor. FGFR1/VEGFR2-IN-1 can be used for cancer research.

HY-E70824

FGFR2 R612T Recombinant Human Active Protein Kinase
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 R612T is a mutant of FGFR3. FGFR2 R612T Recombinant Human Active Protein Kinase is a recombinant FGFR2 R612T protein that can be used to study FGFR2 R612T-related functions.

HY-147715

FGFR3-IN-3	Inhibitor
FGFR3-IN-3 (compound 40a) is a potent and pan-FGFR inhibitor, with IC₅₀s of 2.1 nM, 3.1 nM, 4.3 nM and 74 nM for FGFR1, 2, 3, and 4, respectively. FGFR3-IN-3 can be used for the research of bladder cancer.

HY-135605

PNU-145156E	Inhibitor
PNU-145156E (FCE26644) is an angiogenesis inhibitor with anti-tumor activity. PNU-145156E inhibits the binding of bFGF to its receptor and inhibits bFGF-induced endothelial cell proliferation and motility.

Name
Email *

	Sorry, but the email address you supplied was invalid.

FGFR

FGFR

FGFR Related Products (331)

Recombinant Proteins (68)

Antibodies (11)

FGFR Related Products (331):